Growth Metrics

GeneDx Holdings (WGS) Accumulated Expenses (2020 - 2026)

GeneDx Holdings has reported Accumulated Expenses over the past 7 years, most recently at $24.7 million for Q1 2026.

  • Quarterly Accumulated Expenses rose 75.81% to $24.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $24.7 million through Mar 2026, up 75.81% year-over-year, with the annual reading at $44.7 million for FY2025, 258.91% up from the prior year.
  • Accumulated Expenses was $24.7 million for Q1 2026 at GeneDx Holdings, down from $44.7 million in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $44.7 million in Q4 2025 and troughed at $7.3 million in Q2 2024.
  • The 5-year median for Accumulated Expenses is $18.5 million (2022), against an average of $20.0 million.
  • Year-over-year, Accumulated Expenses crashed 59.04% in 2024 and then skyrocketed 285.52% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $20.3 million in 2022, then crashed by 40.05% to $12.2 million in 2023, then grew by 2.17% to $12.4 million in 2024, then skyrocketed by 258.91% to $44.7 million in 2025, then plummeted by 44.79% to $24.7 million in 2026.
  • Per Business Quant, the three most recent readings for WGS's Accumulated Expenses are $24.7 million (Q1 2026), $44.7 million (Q4 2025), and $26.4 million (Q3 2025).